RIVOGENLECLEUCEL(INNE)RIVOGENLEKLEUCEL(INNC)HUMAN CULTURE EXPANDED GENETICALLY MODIFIED ALLOGENIC T CELLS FOR CELL-BASED THERAPY. CELLS ARE DERIVED FROM ISOLATED BLOOD OF A HEALTHY HUMAN DONOR CHOSEN BY AVAILABLE HLA MATCH (HAPLOIDENTICAL UP TO FULLY MATCHED) AND ARE TRANSDUCED WITH A GIBBON APE LEUKEMIA VIRUS (GALV) PSEUDOTYPED GAMMARETROVIRAL VECTOR CARRYING AN INDUCIBLE CASPASE 9 SUICIDE TRANSGENE AND A TRUNCATED CD19 MARKER GENE ALLOWING SELECTION, AND A DRUG BINDING DOMAIN CONSISTING OF HUMAN FK506 (TACROLIMUS)-BINDING PROTEIN (FKBP12) WITH AN F36V MUTATION. CELLS EXHIBIT ANTI-INFECTIVE ACTIVITY AS ADJUNCTIVE T-CELL THERAPY IN COMBINATION WITH ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, IN COMBINATION WITH AN INDUCIBLE SUICIDE MECHANISM IN THE EVENT OF DONOR T-CELL INDUCED GRAFT VERSUS HOST DISEASE (GVHD).